Still Detox provides 24/7 medically supervised fentanyl addiction treatment for adults in Boca Raton, Florida. Our board-certified Medical Director manages fentanyl withdrawal using COWS-guided protocols, comfort medications, and Medication-Assisted Treatment (MAT) including buprenorphine — in a private, 14-bed setting adjacent to Boca Regional Hospital. The greatest danger of fentanyl is not the withdrawal itself but the overdose that follows relapse. Call now for a confidential, same-day assessment.
Free & confidential — takes about 60 seconds
Joint Commission Accredited
Florida DCF Licensed
LegitScript Certified
Verified by Psychology TodayFentanyl addiction is classified by the DSM-5 as opioid use disorder — a chronic neurological condition defined by compulsive fentanyl use despite significant harm to health, relationships, and daily functioning. Fentanyl is a synthetic opioid that is 50 times more potent than heroin and 100 times more potent than morphine, per NIDA. It acts by binding to mu-opioid receptors in the brain, producing intense analgesia, euphoria, and CNS depression. With repeated use, the opioid receptor system adapts — natural endorphin production is suppressed, receptor sensitivity decreases, and the brain becomes physically dependent on fentanyl to maintain baseline function.
Fentanyl arrives in two forms: pharmaceutical fentanyl (prescription patches, lozenges, nasal sprays) and illicitly manufactured fentanyl (IMF), which is responsible for the majority of overdose deaths in the current crisis. IMF is often mixed into other drugs — counterfeit pills, heroin, cocaine — without the user's knowledge, making every use a potentially lethal event. Still Detox manages fentanyl use disorder alongside the full spectrum of opioid addiction, including heroin and prescription opioids.
Fentanyl withdrawal is not life-threatening in the same way alcohol or benzodiazepine withdrawal is — it does not carry a risk of fatal seizures or cardiovascular collapse during the withdrawal itself. But this clinical distinction misses the most important danger: the overdose that happens after unsupported detox.
When someone stops fentanyl, opioid tolerance drops rapidly — within days. A person who detoxes for one week and then relapses at their previous dose is no longer tolerant to that dose. They are now at extreme risk of a fatal overdose from an amount they previously used without incident. This post-cessation overdose risk is the primary reason that fentanyl detox without Medication-Assisted Treatment (MAT) and residential follow-through carries very high mortality. Per SAMHSA, hospitalization or 24-hour medical care is the preferred setting for opioid detoxification.
At Still Detox, fentanyl detox is managed using COWS (Clinical Opiate Withdrawal Scale) assessments to guide medication decisions. Buprenorphine (Suboxone) is available for induction during detox to manage withdrawal symptoms and reduce craving. Naltrexone (Vivitrol) is available for eligible clients after detox completion. The goal is not just physical stabilization — it is bridge-building to the residential program where long-term recovery begins.
Fentanyl addiction requires a treatment environment that offers the full continuum — COWS-guided medical management, MAT, dual diagnosis care, and the residential therapeutic program that is the difference between detox and recovery.
Our Medical Director, board-certified in addiction medicine, evaluates every client within 24 hours of admission. COWS assessments drive medication decisions throughout withdrawal. Buprenorphine induction is available during detox for appropriate candidates.
Medication-Assisted Treatment with buprenorphine and naltrexone (Vivitrol) is a specialized component of Still Detox's program. Per NIDA and the CDC, MAT substantially reduces opioid overdose mortality and improves long-term recovery outcomes. MAT is not a replacement for treatment — it is part of it.
Located on the University Hospital campus, adjacent to Boca Regional Hospital. Emergency services are immediately accessible for any client requiring acute medical escalation during fentanyl withdrawal or stabilization.
Fentanyl detox flows directly into inpatient residential treatment on the same campus. The post-detox window is the period of highest relapse and overdose risk — residential structure is not optional, it is life-saving.
Every team member, from behavioral health techs through the Medical Director, is fluent in English and Spanish. Complete fentanyl addiction treatment services are available in Spanish.
Unlike most treatment facilities, Still Detox fully accommodates legitimate service animals during fentanyl addiction treatment. Dogs and cats are welcome. Recovery should never require leaving your companion behind.
People come to Still Detox at their most vulnerable. Here is what they say about the clinical care and the life they found on the other side of fentanyl addiction.
Fentanyl withdrawal follows the general opioid withdrawal pattern but is typically more intense than withdrawal from shorter-acting opioids such as heroin or oxycodone, due to fentanyl's extreme potency and lipophilicity — it deposits in fatty tissue and can produce a more prolonged withdrawal in some cases. The timeline differs between immediate-release fentanyl (lozenges, nasal spray, injection) and extended-release formulations (transdermal patches), with patches producing a more delayed and gradual onset.
Fentanyl withdrawal severity is assessed using the COWS (Clinical Opiate Withdrawal Scale), a validated 11-item instrument that quantifies withdrawal severity and guides medication decisions in real time. COWS assessment scores drive buprenorphine dosing and comfort medication adjustments throughout the detox window at Still Detox.
Withdrawal symptoms begin within 12 to 30 hours of the last dose of immediate-release fentanyl. Fentanyl patch withdrawal may be delayed 24 to 36 hours. Early symptoms include anxiety, restlessness, yawning, tearing eyes, runny nose, sweating, goosebumps, and mild muscle aches. COWS assessment begins immediately on admission and drives initial medication decisions.
Symptoms intensify and reach peak severity between days 2 and 4. Muscle and bone pain becomes severe — often described as deep, aching pain throughout the body. Nausea, vomiting, diarrhea, abdominal cramping, insomnia, elevated heart rate and blood pressure, and intense cravings are at their worst. This is the window of highest suffering and the period during which buprenorphine management provides the most significant clinical benefit.
Physical symptoms begin to subside as the opioid receptor system begins recalibrating. Most acute symptoms resolve within 7 to 10 days. Psychological symptoms — depression, anxiety, low motivation, difficulty sleeping — persist. Cravings remain significant during this window and environmental triggers can produce intense craving responses. Clinical monitoring continues throughout.
Post-acute withdrawal syndrome from fentanyl can extend depression, anhedonia, insomnia, anxiety, and cue-triggered cravings for weeks to months. PAWS is a major driver of relapse and overdose death in the period after acute detox resolution. MAT continuation during residential treatment is the evidence-based response to PAWS in opioid use disorder.
Knowing what to expect removes one of the biggest barriers to asking for help. Here is how fentanyl addiction treatment at Still Detox works from first call through residential care.
Your admissions representative gathers your fentanyl use history, current use pattern, co-occurring conditions, and any prior MAT experience. Out-of-network PPO benefits are verified before you commit. Travel, childcare, and logistics are coordinated before your arrival.
A pre-admission call within three days of arrival covers your full opioid history, psychiatric history, and any co-occurring depression, anxiety, trauma, or chronic pain — so the team has a complete clinical picture before you arrive and the MAT plan is ready on day one.
A nurse and behavioral health tech meet you together for a streamlined intake. COWS assessment begins promptly to quantify withdrawal severity. Comfort medications and buprenorphine induction (for appropriate candidates) are available immediately to prevent the acute withdrawal from progressing to peak intensity without support.
Within 24 hours, the Medical Director completes a full history and physical and establishes your individualized treatment plan. MAT decisions — buprenorphine dosing, naltrexone candidacy — are made based on your specific opioid history, clinical presentation, and preferences.
COWS assessments guide medication adjustments throughout the acute window. Comfort medications address nausea, diarrhea, muscle pain, insomnia, and elevated blood pressure. Buprenorphine manages cravings and residual withdrawal symptoms. Typical stay is 7 to 10 days.
After stabilization, you step directly into residential treatment on the same campus. MAT continuation, individual therapy, group therapy, and dual diagnosis treatment address the psychological and behavioral drivers of opioid use disorder without facility transfer or disruption.
The DSM-5 classifies fentanyl addiction as opioid use disorder, using 11 diagnostic criteria. A diagnosis requires 2 or more criteria in a 12-month period. Mild is 2 to 3; moderate is 4 to 5; severe is 6 or more. Per NIDA, fentanyl addiction is a treatable chronic medical condition — not a moral failure.
Using fentanyl in larger amounts or over longer periods than planned. The rapid tolerance development driven by fentanyl's extreme potency means that dose escalation happens faster than with less potent opioids, and the gap between the intended dose and the actual dose widens quickly.
A persistent desire to reduce or stop fentanyl use combined with repeated unsuccessful attempts. The severity of fentanyl withdrawal — described by many as the worst flu-like suffering imaginable — makes self-cessation feel physically impossible without clinical support, and often is.
Spending significant time obtaining fentanyl, using it, or recovering from it. In illicitly manufactured fentanyl use, this includes the time spent navigating supply chains, managing withdrawal between uses, and recovering from overdoses or near-overdoses.
A powerful, often overwhelming urge to use fentanyl, particularly when early withdrawal symptoms emerge. Opioid cravings are neurological in origin — the opioid receptor system, deprived of its external agonist, signals urgently for relief. Cravings are a primary driver of continued use despite the desire to stop.
Fentanyl use that interferes with work performance, family responsibilities, or daily obligations. Opioid intoxication, the cycling between use and withdrawal, and the time required to maintain supply all progressively displace functional capacity.
Persisting with fentanyl use despite conflict with family members or partners caused or worsened by the drug. Secrecy, financial instability, emotional withdrawal, and the behavioral consequences of opioid use disorder create profound relationship damage.
Giving up hobbies, social engagement, or valued activities in order to use fentanyl. Life progressively narrows around the opioid cycle — obtaining, using, withdrawing, obtaining — until most previous interests and relationships have been abandoned.
Using fentanyl while driving, combining with benzodiazepines or alcohol (dramatically increasing respiratory depression risk), or using illicitly manufactured fentanyl with unknown potency and potential adulterants including nitazenes and xylazine (tranq). Every use of IMF carries a risk of fatal overdose regardless of prior tolerance.
Persisting with fentanyl use despite awareness of physical harm including overdose history, respiratory depression episodes, endocarditis from injection use, skin infections, or fentanyl-induced hyperalgesia — a paradoxical condition where long-term opioid use increases pain sensitivity.
Requiring significantly higher fentanyl doses to achieve the same effect, or finding that the same dose produces a markedly diminished response. Fentanyl tolerance develops faster than with less potent opioids due to its extreme mu-receptor affinity, driving rapid dose escalation and deepening physical dependence.
Experiencing muscle and bone pain, sweating, goosebumps, restlessness, insomnia, nausea, vomiting, diarrhea, elevated heart rate, and intense cravings when fentanyl is delayed or stopped. The presence of withdrawal symptoms — and especially the fear of them — is both a hallmark of physical dependence and the primary driver of continued use despite wanting to stop.
Source: DSM-5 opioid use disorder criteria. Per NIDA, fentanyl addiction is a treatable medical condition. Any 2 or more criteria in a 12-month period constitutes a diagnosis. MAT with buprenorphine or naltrexone is the evidence-based first-line treatment.
Talk to Admissions ConfidentiallyThese are real before-and-after moments from people who completed treatment at Still Detox and built lasting recovery. Each one represents a life that fentanyl did not take — and a future that treatment made possible.
Fentanyl withdrawal itself is rarely fatal in healthy adults. The lethal danger comes after: opioid tolerance drops rapidly during abstinence, and someone who relapses after a week of unsupported detox at their pre-detox dose is now highly likely to fatally overdose. This tolerance-loss overdose pattern is one of the leading causes of opioid overdose death and the primary clinical argument for MAT and residential follow-through after detox.
Illicitly manufactured fentanyl has no consistent potency from batch to batch or pill to pill. A person who relapsed on the same supply for months may encounter a dramatically more concentrated batch after a period of detox — with lower tolerance and without the gradual accommodation that previously allowed survival. There is no "safe" relapse with IMF.
Post-acute withdrawal syndrome from fentanyl extends depression, anhedonia, and cue-triggered cravings for months. Without residential therapeutic support addressing the underlying trauma, depression, or chronic pain that drove initial fentanyl use, PAWS symptoms provide continuous neurological pressure toward relapse during the period when overdose death risk is highest.
Still Detox is an out-of-network provider for most insurance plans. Many clients with PPO plans that carry out-of-network benefits apply that coverage toward fentanyl detox, MAT, and residential treatment. Our admissions team verifies your specific benefits at no cost and with no obligation before admission.
We confirm what your plan covers, walk through any out-of-pocket responsibility, and explain flexible payment options including monthly payment plans and promissory arrangements. Cost should never be the reason someone does not receive fentanyl addiction treatment.
Don't see your plan? Call us. Our specialists work with many coverage scenarios and will give you an honest answer about what is covered.
Fentanyl withdrawal produces significant physical discomfort. Our facility pairs hospital-adjacent medical infrastructure with an environment designed to make the most difficult days of recovery as manageable as possible.
IMF arrives in counterfeit pills, powders, and adulterated supplies with unpredictable potency and frequent adulterants including xylazine (tranq) and nitazenes. Still Detox manages stabilization from IMF — including cases involving xylazine co-use, which requires wound care management and modified naloxone response protocols.
Many clients develop fentanyl dependence through legitimate prescription fentanyl patches or lozenges for chronic pain. Still Detox manages detox and coordinates with clients on non-opioid pain management alternatives during and after residential care — discontinuation does not mean abandoning pain management.
Fentanyl is frequently combined with benzodiazepines or alcohol — combinations that dramatically amplify respiratory depression risk. Still Detox has the clinical infrastructure to manage fentanyl withdrawal alongside medically supervised withdrawal from other substances simultaneously under physician supervision.
Fentanyl addiction is treatable. The window between wanting to stop and dying from the next relapse can be very short. Our team is on-site 24 hours a day, same-day assessments are available now, and the residential care that separates detox from overdose statistics begins immediately after stabilization. Call now.
We're here 24/7. Speak with admissions, confidentially and with no obligation.
☎ Call (561) 556-2677Accreditations & Memberships
We understand that there are no shortcuts on the path to recovery, and our compassionate team offers unwavering support and intensive care throughout your healing journey.
Still Detox is a member of Still Behavioral Health Group.
Get Help Now
If you or someone you care about is seeking support for substance abuse and addiction challenges, we are here to offer our assistance. This is where your journey towards healing begins.
© 2026 | Still Detox Drug and Alcohol Treatment Center in Florida
950 NW 9th CT, Boca Raton, FL 33486
